Major Depressive Disorder (MDD) and Antidepressant Medication Are Overrepresented in High-Dose Statin Treatment. 2021

Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Objective: To examine the dose-dependent relationship of different types of statins with the occurrence of major depressive disorder (MDD) and prescription of antidepressant medication. Methods: This cross-sectional study used medical claims data for the general Austrian population (n = 7,481,168) to identify all statin-treated patients. We analyzed all patients with MDD undergoing statin treatment and calculated the average defined daily dose for six different types of statins. In a sub-analysis conducted independently of inpatient care, we investigated all patients on antidepressant medication (statin-treated patients: n = 98,913; non-statin-treated patients: n = 789,683). Multivariate logistic regression analyses were conducted to calculate the risk of diagnosed MDD and prescription of antidepressant medication in patients treated with different types of statins and dosages compared to non-statin-treated patients. Results: In this study, there was an overrepresentation of MDD in statin-treated patients when compared to non-statin-treated patients (OR: 1.22, 95% CI: 1.20-1.25). However, there was a dose dependent relationship between statins and diagnosis of MDD. Compared to controls, the ORs of MDD were lower for low-dose statin-treated patients (simvastatin>0- < =10 mg:OR: 0.59, 95% CI: 0.54-0.64; atorvastatin>0- < =10 mg:OR:0.65, 95%CI: 0.59-0.70; rosuvastatin>0- < =10 mg:OR: 0.68, 95% CI: 0.53-0.85). In higher statin dosages there was an overrepresentation of MDD (simvastatin>40- < =60 mg:OR: 2.42, 95% CI: 2.18-2.70, >60-80 mg:OR: 5.27, 95% CI: 4.21-6.60; atorvastatin>40- < =60 mg:OR: 2.71, 95% CI: 1.98-3.72, >60- < =80 mg:OR: 3.73, 95% CI: 2.22-6.28; rosuvastatin>20- < =40 mg:OR: 2.09, 95% CI: 1.31-3.34). The results were confirmed in a sex-specific analysis and in a cohort of patients taking antidepressants, prescribed independently of inpatient care. Conclusions: This study shows that it is important to carefully re-investigate the relationship between statins and MDD. High-dose statin treatment was related to an overrepresentation, low-dose statin treatment to an underrepresentation of MDD.

UI MeSH Term Description Entries

Related Publications

Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
April 2021, Journal of clinical medicine,
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
February 2017, Psychiatric services (Washington, D.C.),
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
January 2015, Patient preference and adherence,
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
January 2008, International clinical psychopharmacology,
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
July 2021, Journal of clinical medicine,
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
January 2011, In vivo (Athens, Greece),
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
June 2019, Synapse (New York, N.Y.),
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
May 2020, The Journal of clinical psychiatry,
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
August 2014, The pharmacogenomics journal,
Michael Leutner, and Caspar Matzhold, and Alexander Kautzky, and Michaela Kaleta, and Stefan Thurner, and Peter Klimek, and Alexandra Kautzky-Willer
January 2007, Psychotherapy and psychosomatics,
Copied contents to your clipboard!